PartnershipJul 22, 2026, 08:42 AM
Akari Therapeutics Highlights Whitehawk Collaboration for ADC Payloads
AI Summary
Akari Therapeutics' CEO, Abizer Gaslightwala, discussed the company's strategic research collaboration with Whitehawk Therapeutics in a Virtual Investor interview. The collaboration focuses on evaluating Akari's proprietary PH1 spliceosome modulating payload technology in combination with Whitehawk's topoisomerase I inhibitor (TOP1i) ADC platform. Preclinical studies are planned to assess dual payload synergy and support future development of next-generation ADCs, validating Akari's platform.
Key Highlights
- Akari Therapeutics CEO discussed strategic research collaboration with Whitehawk Therapeutics.
- Collaboration evaluates Akari's PH1 spliceosome modulating payload technology.
- Combines Akari's technology with Whitehawk's topoisomerase I inhibitor (TOP1i) ADC platform.
- Planned preclinical studies aim to assess dual payload synergy for next-generation ADCs.
- CEO highlighted increasing industry focus on differentiated ADC payload technologies.
- Akari believes its PH1 platform is well-positioned for next-generation ADC development.
- IND-enabling studies for lead candidate AKTX-101 initiated, targeting First-In-Human trial by mid-2027.
Price Impact
More from AKTX